Join Growin Stock Community!

Pasithea therapeutics corp.KTTA.US Overview

US StockHealthcare
(No presentation for KTTA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

KTTA AI Insights

KTTA Overall Performance

KTTA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

KTTA Recent Performance

-3.90%

Pasithea therapeutics corp.

0.05%

Avg of Sector

-0.31%

S&P500

KTTA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

KTTA Key Information

KTTA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

KTTA Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Price of KTTA

KTTA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

KTTA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.81
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
42.15
PB Ratio
1.66
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.81
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
42.15
PB Ratio
1.66
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is KTTA's latest earnings report released?

    The most recent financial report for Pasithea therapeutics corp. (KTTA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating KTTA's short-term business performance and financial health. For the latest updates on KTTA's earnings releases, visit this page regularly.

  • How much cash does KTTA have?

    At the end of the period, Pasithea therapeutics corp. (KTTA) held Total Cash and Cash Equivalents of 4.22M, accounting for 0.31 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is KTTA's EPS continuing to grow?

    According to the past four quarterly reports, Pasithea therapeutics corp. (KTTA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.41. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of KTTA?

    Pasithea therapeutics corp. (KTTA)'s Free Cash Flow (FCF) for the period is -2.89M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 7.38% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of KTTA?

    The latest valuation data shows Pasithea therapeutics corp. (KTTA) has a Price-To-Earnings (PE) ratio of -0.39 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.